Skip to main
SNN
SNN logo

SNN Stock Forecast & Price Target

SNN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Smith & Nephew demonstrated positive underlying growth of 5.3%, with a notable increase of 15.9% when excluding the impacts from China, indicating resilience in its core markets. The company expects a stronger second half of the year, supported by improved operating leverage and cost efficiencies, with anticipated trading profit margins between 19.0% and 20.0% for 2025. Additionally, growth in key segments, including a 4.7% rise in hips and a 5.5% increase in orthopedics, underscores the firm’s robust performance in the U.S. market, despite challenges in international markets like China.

Bears say

Smith & Nephew's financial outlook appears challenging due to anticipated weaker revenue in Q1 FY25, influenced by factors such as fewer selling days, the impact of China Joint Repair volume-based pricing (VBP), and ongoing distributor inventory reductions. Additionally, the company expects further negative revenue impacts from VBP in its advanced wound therapy segment, alongside a return to normalized growth conditions that may still fall short of prior performance. The orthopedic segment, despite improving, exhibits a return on invested capital (ROIC) significantly below other business units, compounded by risks from evolving US healthcare reimbursement rates and persistent headwinds in the Chinese market.

SNN has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Smith & Nephew (SNN) Forecast

Analysts have given SNN a Hold based on their latest research and market trends.

According to 4 analysts, SNN has a Hold consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Smith & Nephew (SNN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.